Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab

Coates, LC; Rahman, P; Psaradellis, E; Rampakakis, E; Osborne, B; Lehman, AJ; Nantel, F

Nantel, F (reprint author), Janssen Inc, 19 Green Belt Dr, Toronto, ON M1C 1L9, Canada.

RHEUMATOLOGY, 2019; 58 (3): 522

Abstract

Objectives. Treat to target recommendations for PsA state that the target of treatment should be remission or, at the very least, low disease activity......

Full Text Link